Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection

Kidney International

Volumn 63, Issue 6, 2003, Pages 2262-2268

  Kato, Akihiko ^a   Odamaki, Mari ^b   Nakamura, Hajime ^b   Yodoi, Junji ^b   Hishida, Akira ^b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NONE

Author keywords

Hemodialysis; Hepatitis C virus; Iron; Oxidative stress; Thioredoxin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CELLULOSE; FERRITIN; IRON; MALONALDEHYDE; POLYSULFONE; THIOREDOXIN; VIRUS ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; CELL DAMAGE; CONTROLLED STUDY; DIALYSIS MEMBRANE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEPATITIS C VIRUS; HUMAN; IRON THERAPY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; VIREMIA; VIRUS INFECTION;

EID: 0037850823     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.t01-3-00002.x     Document Type: Article

References (34)

1. NAKAYAMA E, AKIBA T, MARUMO F, SATO C: Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 11:1896-1902, 2000
2. ISHIDA H, AGISHI T, KOYAMA I, et al: Hemodialysis paradox: Survey on the incidence rate of hepatocellular carcinoma in antihepatic virus C-antibody-positive chronic hemodialysis patients. Artif Organs 25:58-60, 2001
3. KAYSEN GA: Inflammation and oxidative stress in end-stage renal disease. Adv Nephrol 30:201-214, 2000
4. KOKEN T, SERTESER M, KAHRAMAN A, GOKCE C: Oxidative stress markers in hepatitis C infected hemodialysis patients. J Nephrol 15:302-307, 2002
5. RUBARTELLI A, BAJETTO A, ALLAVENA G, et al: Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 267:24161-24164, 1992
6. TANAKA T, NAKAMURA H, NISHIYAMA A, et al: Redox regulation by thioredoxin superfamily: Protection against oxidative stress and aging. Free Radic Res 33:851-855, 2001
7. HIROTA K, MATSUI M, IWATA S, et al: AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94:3633-3638, 1997
8. FUKUSE T, HIRATA T, YOKOMISE H, et al: Attenuation of ischemia reperfusion injury by human thioredoxin. Thorax 50:387-391, 1995
9. TAKAGI Y, MITSUI A, NISHIYAMA A, et al: Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci USA 96:4131-4136, 1999
10. TANITO M, MASUTANI H, NAKAMURA H, et al: Attenuation of retinal photooxidative damage in thioredoxin transgenic mice. Neurosci Lett 326:142-146, 2002
11. NAKAMURA H, DE ROSA S, ROEDERER M, et al: Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 8:603-611, 1996
12. NAKAMURA H, DE ROSA SO, YODOI J, et al: Chronic elevation of plasma thioredoxin: Inhibition of chemotaxins and curtailment of life expectancy in AIDS. Proc Natl Acad Sci USA 98:2688-2693, 2001
13. JIKIMOTO T, NISHIKUBO Y, KOSHIBA M, et al: Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 38:765-772, 2002
14. NAKAMURA H, BAI J, NISHINAKA Y, et al: Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24:53-60, 2000
15. ADIU A, NAKAMURA H, SAHAF B, et al: Thioredoxin blood level increases after severe burn. Antioxid Redox Signal 2:707-716, 2000
16. KAKISAKA Y, NAKASHIMA T, SUMIDA H, et al: Elevation of serum thioredoxin levels in patients with type 2 diabetes. Horm Metab Res 34:160-164, 2002
17. KISHIMOTO C, SHIOJI K, NAKAMURA H, et al: Serum thioredoxin (TRX) levels in patients with heart failure. Jpn Circ J 65:491-494, 2001
18. SUMIDA Y, NAKASHIMA T, YOH T, et al: Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 33:616-622, 2000
19. SUMIDA Y, NAKASHIMA T, YOH T, et al: Serum thioredoxin elucidates the significance of serum ferritin as a marker of oxidative stress in chronic liver disease. Liver 21:295-299, 2001
20. NAKASHIMA T, SUMIDA Y, YOH T, et al: Thioredoxin levels in the sera of untreated viral hepatitis patients and those treated with glycyrrhizin or ursodeoxycholic acid. Antioxid Redox Signal 2:687-694, 2000
21. FUJII S, NANBU Y, KONISHI I, et al: Immunohistochemical localization of adult T-cell leukemia-derived factor, a human thioredoxin homologue, in human fetal tissues. Virchows Arch A Pathol Anat Histopthol 419:317-326, 1991
22. YASUDA K, OKUDA K, ENDO N, et al: Hypoaminotransferasemia in patients undergoing long-term hemodialysis: Clinical and biochemical appraisal. Gastroenterology 109:1295-1300, 1995
23. ROZELL B, HANSON HA, LUTHMAN M, HOLMGREN A: Immunohistochemical localization of thioredoxin and thioredoxin reductase in adult rats. Eur J Cell Biol 38:79-88, 1985
24. BERTINI R, HOWARD OMZ, DONG HF, et al: Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemo-attractant for neutrophils, monocytes, and T cells. J Exp Med 189:1783-1789, 1999
25. FABRIZI F, LUNGHI G, ANDRULLI S, et al: influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol Dial Transplant 12:1394:1398, 1997
26. NKF-DOQI Clinical practice guidelines for the treatment of anemia of chronic renal failure: Am J Kidney Dis 30(Suppl 2):S192-S240, 1997
27. HUANG KY, WU DJ, WU KD, et al: Serum ferritin level required for adequate response to recombinant human erythropoietin in haemodialysis patients with hepatitis C virus infection. Nephrol Dial Transplant 13:2709-2710, 1998
28. LIM PS, WEI YH, YU YL, KHO B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14:2680-2687, 1999
29. ROOB JM, KHOSCHSORUR G, TIRAN A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549, 2000
30. HERRERA J, NAVA M, ROMERO F, RODRIGUEZ-ITURBE B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37:750-757, 2001
31. FELDMAN HI, SANTANNA J, GUO W, et al: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13:734-744, 2002
32. KALANTAR-ZADEH K, DON BR, RODRIGUEZ RA, et al: Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 37:564-572, 2001
33. ANNUK M, FELLSTROM B, AKERBLOM O, et al: Oxidative stress markers in pre-uremic patients. Clin Nephrol 56:308-314, 2001
34. OKUDA M, INOUE N, AZUMI H, et al: Expression of glutaredoxin in human coronary arteries: Its potential role in antioxidant protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21:1483-1487, 2001